| Drug Name |
Dabrafenib |
| Drug ID |
BADD_D00566 |
| Description |
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013 for the treatment of melanoma [L2718].
In May 2018, Tafinlar (dabrafenib) and Mekinist ([DB08911]) in combination have been approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene [L2714]. |
| Indications and Usage |
Dabrafenib is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. |
| Marketing Status |
Not Available |
| ATC Code |
L01EC02 |
| DrugBank ID |
DB08912
|
| KEGG ID |
D10064
|
| MeSH ID |
C561627
|
| PubChem ID |
44462760
|
| TTD Drug ID |
D05ROI
|
| NDC Product Code |
0078-0682; 0078-0681; 52482-007 |
| Synonyms |
dabrafenib | GSK 2118436 | GSK2118436 | GSK-2118436 |
